Can a new eye drop boost laser results for glaucoma patients?

NCT ID NCT06865144

Ongoing Disease control Sponsor: East Coast Institute for Research Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether Rhopressa eye drops can further lower eye pressure in people with glaucoma or high eye pressure who recently had laser surgery (SLT) in both eyes. About 70 adults will receive either Rhopressa or placebo drops daily for several weeks. The goal is to see if the drug provides extra pressure reduction beyond the laser alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Netarsudil ophthalmic solution 0.02% (Rhopressa eye drops)
What this could lead to: If it works, this could show that Rhopressa safely lowers eye pressure after laser treatment, offering an additional option for glaucoma management.
What could go wrong: This is a small, early-phase study with only 70 participants, so results may not apply to everyone. The drug may not lower pressure enough or could cause side effects like eye redness or irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OCULAR HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Contacts and locations

Locations

East Coast Institute for Research at Florida Eye Specialists

Jacksonville, Florida, 32256, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.